Projects per year
Professor Andrew Spencer is Head of the Malignant Haematology and Stem Cell Transplantation Service at The Alfred Hospital, Professor of Haematology at Monash University, Head of the Myeloma Research Group and Co-Director of the ACRF Blood Cancer Therapeutics Centre at the Australian Centre for Blood Diseases, all in Melbourne, Australia.
Prof Spencer completed his medical training in clinical and laboratory haematology in Brisbane and Sydney in 1992. He then was awarded a LRF (UK) Fellowship and spent 3 years at The Royal Postgraduate Medical School, London, United Kingdom where he undertook research into B-cell clonality in chronic myeloid leukemia and was awarded a Doctorate in Medicine from the University of London. Subsequently he moved to The Alfred Hospital where he established an independent translational research program. He was appointed Head of Malignant Hematology and Stem Cell Transplantation Services in 2007 and established a first-in-human and early phase hematology clinical research unit at the hospital in 2009.
Prof Spencer has 185 peer reviewed publications with citations in excess of 12,600 and holds 4 international patents in multiple myeloma (MM) therapeutics. Since 2013 he has been an invited speaker at 40 international meetings on genomics, therapeutics and disease monitoring in MM and is an invited investigator of the International Myeloma Foundation (IMF) Black Swan Research Initiative devising and implementing global minimal residual disease strategies for MM. He serves on the scientific advisory boards of the IMF and the International Myeloma Working Group. He chairs the Myeloma and Related Diseases Registry that he established in 2012 and the Australasian Myeloma Research Consortium. He sits on the steering committee for the global MM registry initiative INSIGHT.
The research program of Professor Andrew Spencer aims to:
(1) identify more effective and rationale novel therapeutic strategies for MM through the identification of drug resistance processes and/or biomarkers of drug responsiveness (employing transcriptional and proteomic studies in mouse models and primary tumours) with rapid translational of synergistic drug combinations into early phase investigator-initiated clinical trials, and
(2) identify mechanisms of MM disease progression, with a particular focus on the role of the cell surface phosphatase CD45, and
(3) explore the role of different modalities of minimal residual disease (MRD) detection in MM to optimise their utility in clinical practice.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research area keywords
- biomarkers of drug responsiveness
- blood cancer
- clinical research
- drug resistance
- ell surface phosphatase CD45
- haematological malignancies
- mouse model
- multiple myeloma
- translational research
- novel therapeutics
- epigenetic therapy
Dive into details
Select a country/territory to view shared publications and projects
A Multi-arm Phase 1b Study of Talquetamab with Other Anticancer Therapies in Participants with Multiple Myeloma.
Spencer, A. & Kennedy, N.
9/03/22 → 31/12/27
A Phase Ib, Open-label, Multicenter, Dose- escalation study to evaluate the Safety and Pharmacokinetics of Xmab24306 in combination with Daratumumab in patients with relapsed/refractory Multiple Myeloma.
Spencer, A., Murphy, N. & Kennedy, N.
25/02/22 → 31/12/27
A Phase 1b, Dose Escalation and Expansion Study of Lemzoparlimab with or without Dexamethasone and in Combination With Anti- Myeloma Regimens for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Spencer, A., Keane, C., Murphy, N., Hocking, J. & Kennedy, N.
21/02/22 → 31/12/27
A phase 2 study of PHE885 B-cell maturation antigen (BCMA)-directed CAR-T cells in adult participants with relapsed and refractory multiple myeloma.
Spencer, A. & Kennedy, N.
18/02/22 → 31/12/27
More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: the MY-PROMPT-2 trial
1/02/22 → 31/01/27
A meta-analysis of palifermin efficacy for the management of oral mucositis in patients with solid tumours and haematological malignancyCoutsouvelis, J., Corallo, C., Spencer, A., Avery, S., Dooley, M. & Kirkpatrick, C. M., Apr 2022, In: Critical Reviews in Oncology/Hematology. 172, 18 p., 103606.
Research output: Contribution to journal › Review Article › Research › peer-review
Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In VivoSavvidou, I., Khong, T., Whish, S., Carmichael, I., Sepehrizadeh, T., Mithraprabhu, S., Horrigan, S. K., de Veer, M. & Spencer, A., 1 Feb 2022, In: Cancers. 14, 3, 17 p., 840.
Research output: Contribution to journal › Article › Research › peer-reviewOpen Access
Māori and Pacific Peoples With Multiple Myeloma in New Zealand are Younger and Have Inferior Survival Compared to Other Ethnicities: A Study From the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)Moore, E. M., Blacklock, H., Wellard, C., Spearing, R., Merriman, L., Poplar, S., George, A., Baker, B., Chan, H., McQuilten, Z. K., Wood, E. M., Spencer, A. & on behalf of the MRDR investigators, Aug 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, 8, p. e762-e769 8 p.
Research output: Contribution to journal › Article › Research › peer-review
Palifermin, administered for three doses only, reduces mucositis in patients undergoing HSCT and receiving chemoradiotherapy conditioningCoutsouvelis, J., Dooley, M., Kirkpatrick, C. M., Avery, S., Hopkins, R. & Spencer, A., 2022, (Accepted/In press) In: Bone Marrow Transplantation. 3 p.
Research output: Contribution to journal › Letter › Other › peer-reviewOpen Access
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)Kalff, A., Khong, T., Ramachandran, M., Joy Ho, P., Mollee, P., D’Rozario, J., Taylor, K., Estell, J., Norton, S., Kemp, R., Mitchell, A. J., Reynolds, J., Kennedy, N., Quach, H. & Spencer, A., Jan 2022, In: Haematologica. 107, 1, p. 321-325 5 p.
Research output: Contribution to journal › Letter › Research › peer-reviewOpen Access